IN2012DN00640A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00640A
IN2012DN00640A IN640DEN2012A IN2012DN00640A IN 2012DN00640 A IN2012DN00640 A IN 2012DN00640A IN 640DEN2012 A IN640DEN2012 A IN 640DEN2012A IN 2012DN00640 A IN2012DN00640 A IN 2012DN00640A
Authority
IN
India
Prior art keywords
variable domains
hosts
ligands
vectors
compositions
Prior art date
Application number
Inventor
Coulstock Edward
De Angelis Elena
Liu Haiqun
Schon Oliver
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2012DN00640A publication Critical patent/IN2012DN00640A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.
IN640DEN2012 2009-07-16 2010-07-14 IN2012DN00640A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22602809P 2009-07-16 2009-07-16
US30755410P 2010-02-24 2010-02-24
PCT/EP2010/060112 WO2011006915A2 (en) 2009-07-16 2010-07-14 Improved anti-serum albumin binding single variable domains

Publications (1)

Publication Number Publication Date
IN2012DN00640A true IN2012DN00640A (en) 2015-08-21

Family

ID=42829253

Family Applications (1)

Application Number Title Priority Date Filing Date
IN640DEN2012 IN2012DN00640A (en) 2009-07-16 2010-07-14

Country Status (15)

Country Link
US (2) US8679496B2 (en)
EP (1) EP2454285A2 (en)
JP (1) JP2012532620A (en)
KR (1) KR20120038494A (en)
CN (1) CN102574914A (en)
AU (1) AU2010272590B2 (en)
BR (1) BR112012001681A2 (en)
CA (1) CA2768462A1 (en)
EA (1) EA201270174A1 (en)
IL (1) IL217520A0 (en)
IN (1) IN2012DN00640A (en)
MX (1) MX2012000765A (en)
SG (1) SG177601A1 (en)
WO (1) WO2011006915A2 (en)
ZA (1) ZA201200276B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012517818A (en) * 2009-02-19 2012-08-09 グラクソ グループ リミテッド Improved anti-TNFR1 polypeptides, antibody variable domains and antagonists
EA201270174A1 (en) * 2009-07-16 2012-07-30 Глэксо Груп Лимитед SEPARATE BINDING VARIABLE DOMAINS WITH IMPROVED PROPERTIES DIRECTED AGAINST SERUM ALBUMIN
JP2013538566A (en) * 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Improved antiserum albumin binding variants
JP2014501515A (en) * 2010-12-01 2014-01-23 グラクソ グループ リミテッド Improved antiserum albumin binding single variable domain
SG11201401649VA (en) 2011-11-11 2014-07-30 Ucb Pharma Sa Albumin binding antibodies and binding fragments thereof
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2017041114A2 (en) * 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
NO2768984T3 (en) 2015-11-12 2018-06-09
CA3005061A1 (en) * 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
MX2018006246A (en) 2015-11-18 2018-08-01 Merck Sharp & Dohme Ctla4 binders.
MY189018A (en) 2015-11-18 2022-01-19 Merck Sharp & Dohme Pd1 and/or lag3 binders
EP3377526A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
CN108473564B (en) 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 Improved serum albumin binders
AU2017373746A1 (en) * 2016-12-07 2019-05-30 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
SG11201906341XA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
MX2019008496A (en) 2017-01-17 2019-09-18 Ablynx Nv Improved serum albumin binders.
US11028166B2 (en) 2017-02-16 2021-06-08 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
EP3694873A1 (en) 2017-10-10 2020-08-19 Numab Therapeutics AG Multispecific antibody
EP3927740A4 (en) * 2019-02-22 2023-03-01 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
WO2021205183A1 (en) 2020-04-09 2021-10-14 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
MX2023006650A (en) 2020-12-07 2023-06-21 UCB Biopharma SRL Multi-specific antibodies and antibody combinations.
EP4288451A1 (en) 2021-02-02 2023-12-13 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2005500034A (en) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド Antibody that blocks activation of receptor protein tyrosine kinase, screening method thereof, and use thereof
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
ATE328906T1 (en) 2002-06-28 2006-06-15 Domantis Ltd DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE
PT1737962E (en) 2004-03-24 2010-12-03 Domantis Ltd Gas1 universal leader
EA012622B1 (en) 2004-06-01 2009-10-30 Домэнтис Лимитед Bispecific fusion antibodies with enhanced serum half-life
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
NZ555464A (en) * 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
EP1957537A2 (en) * 2005-12-01 2008-08-20 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
KR20080077261A (en) * 2005-12-06 2008-08-21 도만티스 리미티드 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
CA2636854A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
KR20100018040A (en) 2007-06-06 2010-02-16 도만티스 리미티드 Methods for selecting protease resistant polypeptides
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins
US8906035B2 (en) * 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
JP2011524166A (en) * 2008-06-06 2011-09-01 ダニスコ・ユーエス・インク Compositions and methods comprising mutant microbial proteases
US10198891B2 (en) * 2008-06-06 2019-02-05 Epona Llc System and method for regulating fuel transactions
EA201270174A1 (en) * 2009-07-16 2012-07-30 Глэксо Груп Лимитед SEPARATE BINDING VARIABLE DOMAINS WITH IMPROVED PROPERTIES DIRECTED AGAINST SERUM ALBUMIN

Also Published As

Publication number Publication date
ZA201200276B (en) 2012-09-26
WO2011006915A3 (en) 2011-03-03
MX2012000765A (en) 2012-02-13
US20140140996A1 (en) 2014-05-22
JP2012532620A (en) 2012-12-20
KR20120038494A (en) 2012-04-23
WO2011006915A2 (en) 2011-01-20
EA201270174A1 (en) 2012-07-30
BR112012001681A2 (en) 2019-09-24
CN102574914A (en) 2012-07-11
IL217520A0 (en) 2012-02-29
EP2454285A2 (en) 2012-05-23
US20120114647A1 (en) 2012-05-10
US8679496B2 (en) 2014-03-25
AU2010272590A1 (en) 2012-02-02
CA2768462A1 (en) 2011-01-20
AU2010272590B2 (en) 2013-10-10
SG177601A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
IN2012DN00640A (en)
MX2011008752A (en) Improved anti-serum albumin binding variants.
MX2012013406A (en) Improved anti-serum albumin binding variants.
MX2011008749A (en) Improved anti-serum albumin binding variants.
CY1119567T1 (en) Therapeutic Peptides
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2
MX2012003939A (en) Drug fusions and conjugates with extended half life.
MX2015011075A (en) Therapeutic peptides.
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
WO2013130683A3 (en) Xten conjugate compositions and methods of making same
EA201992456A2 (en) SELF-STABILIZING LINKER CONJUGATES
UA110370C2 (en) Conjugates of amatoxin with improved linkages
WO2011123820A3 (en) Single isomeric conjugates of rhodamine dyes
WO2011086143A3 (en) Liver targeting domain antibodies
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
WO2011112566A3 (en) Basigin binding proteins
MX2013002055A (en) Improved anti-serum albumin binding variants.
CA3036643C (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
MX2015014198A (en) Antibodies targeting m-csf.
WO2014044793A3 (en) Cd22-binding peptides
EP2569327A4 (en) Eif4e binding peptides
MX2016008478A (en) Novel anti adam17 antibody and its use for the treatment of cancer.
WO2008005470A3 (en) Polypeptides that bind membrane proteins
WO2016005474A8 (en) Site selective conjugation of an oligonucleotide conjugate or a small molecule to a metal binding protein
WO2012136792A3 (en) Cck compositions